Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer

We propose a probabilistic model to quantify the cost-benefit of mass Vaccination Scenarios (VSs) against COVID-19. Through this approach, we conduct a six-month simulation, from August 31st, 2021 to March 3rd, 2022, of nine VSs, i.e., the three primary vaccine brands in Brazil (CoronaVac, AstraZene...

Descripción completa

Detalles Bibliográficos
Autores principales: Siqueira, Paulo Gabriel, Duarte, Heitor Oliveira, Moura, Márcio das Chagas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117164/
https://www.ncbi.nlm.nih.gov/pubmed/35610105
http://dx.doi.org/10.1016/j.vaccine.2022.05.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117164/
https://www.ncbi.nlm.nih.gov/pubmed/35610105
http://dx.doi.org/10.1016/j.vaccine.2022.05.038

Ejemplares similares